Drugs for Speech Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 22)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Dopamine |
Approved |
Phase 2, Phase 3 |
|
51-61-6, 62-31-7 |
681
|
Synonyms:
(3H)-Dopamine
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-dihydroxyphenyl)ethylamine
2-(3,4-Dihydroxyphenyl)ethylamine
2-benzenediol
3,4 Dihydroxyphenethylamine
3,4-dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-aminoethyl)catechol
4-(2-Aminoethyl)catechol
4-(2-aminoethyl)pyrocatechol
4-(2-aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
a-(3,4-Dihydroxyphenyl)-b-aminoethane
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL 279
BIDD:ER0506
Biomol-NT_000001
BPBio1_001123
BSPBio_001932
C03758
CHEBI:18243
CHEMBL59
CID681
cMAP_000036
cMAP_000065
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
dopamine
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopamine hydrochloride
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydrochloride, dopamine
|
Hydroxytyramin
hydroxytyramine
Hydroxytyramine
IDI1_000780
intropin
Intropin
Intropin [*hydrochloride*]
IP 498
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L000232
L-DOPAMINE
LDP
Lopac0_000586
Lopac-H-8502
LS-159
Medopa (TN)
m-Hydroxytyramine hydrochloride
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
Spectrum_001012
SPECTRUM1505155
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
ST048774
STK301601
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
|
|
2 |
|
Ecopipam |
Investigational |
Phase 2, Phase 3 |
|
112108-01-7 |
|
3 |
|
Dopamine Agents |
|
Phase 2, Phase 3 |
|
|
|
4 |
|
Tranquilizing Agents |
|
Phase 2, Phase 3 |
|
|
|
5 |
|
Central Nervous System Depressants |
|
Phase 2, Phase 3 |
|
|
|
6 |
|
Antipsychotic Agents |
|
Phase 2, Phase 3 |
|
|
|
7 |
|
Dopamine Antagonists |
|
Phase 2, Phase 3 |
|
|
|
8 |
|
Psychotropic Drugs |
|
Phase 2, Phase 3 |
|
|
|
9 |
|
Botulinum Toxins |
|
Phase 1 |
|
|
|
10 |
|
Miconazole |
Approved, Investigational, Vet_approved |
|
|
22916-47-8 |
4189
|
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
Aflorix(nitrate)
AKOS001574474
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
Brentan
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
Conofite(nitrate)
CPD-4501
D00416
Dactarin
Daktarin IV
DB01110
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Esteve brand OF miconazole
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
Janssen cilag brand OF miconazole
Janssen-cilag brand OF miconazole
Johnston and johnston brand OF miconazole nitrate
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
Lotrimin AF(nitrate)
LS-78378
MCZ
Micantin (nitrate)
Miconasil nitrate
Miconasil Nitrate
Miconazol
|
Miconazol [INN-Spanish]
miconazole
Miconazole
Miconazole (JP15/USP/INN)
Miconazole [USAN:BAN:INN:JAN]
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole esteve brand
Miconazole janssen-cilag brand
Miconazole nitrate
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MJR 1762
MLS002222203
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
Nitrate, miconasil
Nitrate, miconazole
Novo-Miconazole Vaginal Ovules
NSC 170986
NSC169434
NSC170986
Oprea1_091955
Prestwick_335
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
Spectrum_000965
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
STK834405
STOCK1S-93556
UNII-7NNO0D7S5M
Vusion
Zimycan
|
|
11 |
|
Acetylcholine |
Approved, Investigational |
|
|
51-84-3 |
187
|
Synonyms:
2-(Acetyloxy)-N,N,N-trimethylethanaminium
Acetilcolina cusi
Acetyl choline ion
Acetylcholine bromide
Acetylcholine cation
acetylcholine chloride
Acetylcholine chloride
Acetylcholine fluoride
Acetylcholine hydroxide
Acetylcholine iodide
Acetylcholine L tartrate
Acetylcholine L-tartrate
Acetylcholine perchlorate
Acetylcholine picrate
Acetylcholine picrate (1:1)
Acetylcholine sulfate (1:1)
Acetylcholinium: acetyl-choline
ACh
Alcon brand OF acetylcholine chloride
|
Azetylcholin
Bournonville brand OF acetylcholine chloride
Bromide, acetylcholine
Bromoacetylcholine
Chloroacetylcholine
Choline acetate
Choline acetate (ester)
Choline acetic acid
Ciba vision brand OF acetylcholine chloride
Cusi, acetilcolina
Fluoride, acetylcholine
Hydroxide, acetylcholine
Iodide, acetylcholine
Iolab brand OF acetylcholine chloride
L-Tartrate, acetylcholine
Miochol
O-Acetylcholine
Perchlorate, acetylcholine
|
|
12 |
|
Silver sulfadiazine |
Approved, Vet_approved |
|
|
22199-08-2 |
441244
|
Synonyms:
(4-Amino-N-pyrimidin-2-ylbenzenesulphonamidato-NN,O1)silver
22199-08-2
481181_ALDRICH
4-Amino-N-(2-pyrimidinyl)benzenesulfonamide silver salt
4-amino-N-pyrimidin-2-ylbenzenesulfonamide
Abbott Brand of Silver Sulfadiazine
AC-19319
AC1L1KQS
AC1L9ATF
AC1L9Q6O
AC1NUR63
AC1O8LAG
AC-3535
AKOS005111099
AKOS005111434
Aldo Brand of Silver Sulfadiazine
ARONIS23842
Benzenesulfonamide, 4-amino-N-2-pyrimidinyl-, monosilver(1+) salt
Benzenesulfonamide,4-amino-N-2-pyrimidinyl-, silver complex
Brandiazin
C10H9N4O2S.Ag
CHEBI:9142
CHEMBL1200766
CID11947738
CID31011
CID441244
CID452254
CID5459124
D00433
D012837
DB05245
Dermazin
Dermazine
EINECS 244-834-5
Flamazine
Flammazine
Geben
I06-0145
I06-145
LS-147839
Major Brand of Silver Sulfadiazine
medphano Brand of Silver Sulfadiazine
MLS000069662
MolPort-003-934-423
MolPort-003-986-619
MolPort-006-395-987
Monarch Brand of Silver Sulfadiazine
N(sup 1)-2-Pyrimidinylsulfanilamide monosilver(1+) salt
N1-2-Pyrimidinylsulfanilamide monosilver(1+) salt
NSC 625324
NSC625324
|
Par Brand 1 of Silver Sulfadiazine
Par Brand 2 of Silver Sulfadiazine
Par Brand 3 of Silver Sulfadiazine
Pharmascience Brand of Silver Sulfadiazine
Rhone Poulenc Rorer Brand of Silver Sulfadiazine
Rhone-Poulenc Rorer Brand of Silver Sulfadiazine
S0595
Sherwood Brand of Silver Sulfadiazine
Sicazine
Silbertone
Sildaflo
Silvadene
Silvadene (TN)
Silvederma
silver
silver (4-aminophenyl)sulfonyl-pyrimidin-2-ylazanide
silver 4-amino-N-pyrimidin-2-ylbenzenesulfonamide
silver sulfadiazinate
Silver sulfadiazinate
silver sulfadiazine
Silver sulfadiazine
Silver Sulfafdiazine
Silver sulphadiazine
silver(1+) [(4-aminophenyl)sulfonyl](pyrimidin-2-yl)azanide
Silver(I) sulfadiazine
Smith & Nephew Brand of Silver Sulfadiazine
SMR000059233
Solvay Brand of Silver Sulfadiazine
SSD
SSD (1% Silver Sulfadiazine Cream USP)
SSD AF
STL069502
Sulfadiazin silber
Sulfadiazin, silbersalz
Sulfadiazine silver
SULFADIAZINE SILVER
Sulfadiazine silver (JP15)
Sulfadiazine silver salt
Sulfadiazine silverSilvadene
Sulfadiazine, silver
Sulfadiazine, silver (USP)
Sulfadiazine, Silver [USAN]
Sulfafdiazine, Silver
Sulfanilamide, N(sup 1)-2-pyrimidinyl-, monosilver(1+) salt
Sulfanilamide,N1-2-pyrimidinyl-, monosilver(1+) salt
Sulfargen
Thermazene
TL8001845
UNII-W46JY43EJR
Zenith Brand of Silver Sulfadiazine
|
|
13 |
|
Tacrolimus |
Approved, Investigational |
|
|
104987-11-3 |
445643
439492
6473866
|
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
Advagraf
AKOS005145901
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
Anhydrous, tacrolimus
BCBcMAP01_000194
Bio-0921
Bio2_000470
Bio2_000950
BRD-K35452788-001-02-1
BSPBio_001279
BSPBio-001279
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
Cilag brand OF tacrolimus
CPD000466356
CPD-10016
D08556
DB00864
DivK1c_001040
FK 506
FK5
Fk-506
FK506
FK-506
FR 900506
FR900506
|
FR-900506
FT-0082660
Fujimycin
Fujisawa brand OF tacrolimus
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
Janssen brand OF tacrolimus
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
nchembio.2007.23-comp2
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Prograft
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
tacrolimus
Tacrolimus
Tacrolimus (anhydrous)
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus anhydrous
tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
|
|
14 |
|
Antifungal Agents |
|
|
|
|
|
15 |
|
Neurotransmitter Agents |
|
|
|
|
|
16 |
|
Acetylcholine Release Inhibitors |
|
|
|
|
|
17 |
|
Cholinergic Agents |
|
|
|
|
|
18 |
|
Pharmaceutical Solutions |
|
|
|
|
|
19 |
|
Immunologic Factors |
|
|
|
|
|
20 |
|
Immunosuppressive Agents |
|
|
|
|
|
21 |
|
Liver Extracts |
|
|
|
|
|
22 |
|
Calcineurin Inhibitors |
|
|
|
|
|
Interventional clinical trials:
(show top 50)
(show all 55)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
An Open-label Study to Evaluate the Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering). |
Unknown status |
NCT02909088
|
Phase 2, Phase 3 |
Ecopipam 50mg;Ecopipam 100mg |
2 |
Treatment for Adductor Spasmodic Dysphonia by Type 2 Thyroplasty Using Titanium Bridges |
Completed |
NCT02528006
|
Phase 2, Phase 3 |
|
3 |
Lateral Cord Magnetic Stimulation For Refractory Spastic Cerebral Palsy - Multicenter Double Blind Randomized and Controlled Trial |
Not yet recruiting |
NCT03676439
|
Phase 2, Phase 3 |
|
4 |
Left, Right, or Bilateral Thalamic Deep Brain Stimulation for Voice Tremor: A Prospective, Randomized, Double-Blinded Trial |
Unknown status |
NCT02960243
|
Phase 1, Phase 2 |
|
5 |
Word by Word: Building Sentences With Preschoolers Who Use AAC |
Recruiting |
NCT03538925
|
Phase 2 |
|
6 |
Biofeedback and Speech Disorders |
Completed |
NCT01905449
|
Phase 1 |
|
7 |
Laryngeal Resistance in Abductor Spasmodic Dysphonia |
Completed |
NCT00015795
|
Phase 1 |
|
8 |
Treating Speech Disorders in Patients With Parkinson's Disease Using Altered Auditory Feedback |
Completed |
NCT00488657
|
Phase 1 |
|
9 |
ASSIST: Child Apraxia Speech Treatment |
Recruiting |
NCT03903120
|
Phase 1 |
|
10 |
Influence of Medical Clowning in Videofluoroscopic Examination of Pediatric Speech Disorder |
Unknown status |
NCT02701322
|
|
|
11 |
Intervention Software for Children With Speech Sound Disorders |
Unknown status |
NCT02490826
|
|
|
12 |
Spreken Verfijnen in de Kleuterklas: De Ontwikkeling Van Een Spraakdidactiek Als Uitbreiding op de Gangbare Taaldidactiek in Het Kleuteronderwijs |
Unknown status |
NCT02313025
|
|
|
13 |
Dysarthria in Parkinson's Disease: Lusophony vs. Francophony Comparison |
Unknown status |
NCT02753192
|
|
|
14 |
Effects of a Game-based Virtual Reality Video Capture Training Program Plus Occupational Therapy on Manual Dexterity in Patients With Multiple Sclerosis: a Randomizaed Controlled Trial |
Unknown status |
NCT03186612
|
|
|
15 |
Characteristics of Idiopathic Familial Speech Disorders |
Completed |
NCT00001551
|
|
|
16 |
Brain Activation During Developmental Speech Production and Speech Perception |
Completed |
NCT00004991
|
|
|
17 |
A Speech Disorders Severity Index to Measure the Impact of Oral and Pharyngeal Cavity on Speech Production |
Completed |
NCT02875795
|
|
|
18 |
Lingual Frenum and Possible Alterations in the Articulation of Phonemes |
Completed |
NCT01180309
|
|
|
19 |
Study of Speech Disorders , Voice and Swallowing in Primary Dystonia Oromandibular |
Completed |
NCT03380676
|
|
|
20 |
Visual Feedback of Tongue by Ultrasound Echography for Speech Trouble Rehabilitation |
Completed |
NCT02752425
|
|
|
21 |
Treatment Efficacy for Developmental Motor Speech Disorders: A PROMPT Randomized Control Trial |
Completed |
NCT02105402
|
|
|
22 |
Stuttering Severity and Anxiety in Egyptian School-age Children |
Completed |
NCT03160586
|
|
|
23 |
Investigating the Use of Transcranial Magnetic Stimulation (TMS) for Primary Progressive Apraxia of Speech (PPAOS) |
Completed |
NCT03028324
|
|
|
24 |
Constraint Induced Aphasia Therapy in Stroke Patients in Acute Stage. |
Completed |
NCT02804412
|
|
|
25 |
Enhancing Speech Fluency With Non-invasive Brain Stimulation in Developmental Stuttering |
Completed |
NCT02288598
|
|
|
26 |
Development of Normative Ultrasound Databases of Tongue Surface Configuration |
Completed |
NCT00001218
|
|
|
27 |
Brain Connectivity Supporting Language Recovery in Aphasia |
Completed |
NCT02416856
|
|
|
28 |
Exploration of the Diagnostic Capabilities of Ultrasound of the Oropharynx and Larynx |
Completed |
NCT00001167
|
|
|
29 |
Singing in Groups for Parkinson's Disease; A Pilot Study of Group Singing |
Completed |
NCT01163331
|
|
|
30 |
The Follow Study of Speech Functions in Preschool Children With Cerebral Palsy: Clinical Measures and Acoustic Analysis |
Completed |
NCT02378987
|
|
|
31 |
Software for Alternative Communication |
Completed |
NCT02847923
|
|
|
32 |
Les Cartes Sensori-motrices De La Parole : Corrélats Neuroanatomiques Des Systèmes De Perception Et De Production Des Voyelles Du Français |
Completed |
NCT00889317
|
|
|
33 |
Apraxia of Speech: A Comparison of EPG Treatment & Sound Production Treatment |
Completed |
NCT02554513
|
|
|
34 |
Effect of Oral Motor Exercises and Breathing Exercises for Dysphagia in Parkinson Disease: Randomized Clinical Trial |
Completed |
NCT01420796
|
|
|
35 |
Word-Retrieval for Aphasia: Facilitation of Generalization |
Completed |
NCT00125242
|
|
|
36 |
Evaluation of the Effects of Response Elaboration Training for Aphasia |
Completed |
NCT00125216
|
|
|
37 |
The Effect of Oral Candidiasis on the Speech Production, Feeding Skills, and Self-Concept of Children and Adolescents With Symptomatic HIV Infection |
Completed |
NCT00001448
|
|
|
38 |
TeleRehab for Patients With Post-Stroke Communication Deficits Using Mobile Technology |
Completed |
NCT02615132
|
|
|
39 |
Evaluation of Language and Sensorimotor Constraints of Very Premature Babies at the Age of 3 Years 1 / 2 Without Cerebral Palsy. Randomised Study of Stimulation Training Implicit in Children Vulnerable |
Completed |
NCT01426659
|
|
|
40 |
REFIT Hearing: Remote Fitting of Hearing Aids |
Completed |
NCT02589561
|
|
|
41 |
The Effect of Different Feeding Methods and Non-nutritive Sucking Behaviours on Child Speech Development |
Recruiting |
NCT03315416
|
|
|
42 |
Age-related Correlates of Treatment Efficacy and Efficiency for Late-acquired Sounds |
Recruiting |
NCT03663972
|
|
|
43 |
Voice-related Outcomes in Response to Intensive Versus Traditional Therapy Programs |
Recruiting |
NCT03129880
|
|
|
44 |
A Training Protocol for the Use of Botulinum Toxin in the Treatment of Neurological Disorders |
Recruiting |
NCT00001208
|
|
|
45 |
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech |
Recruiting |
NCT03313011
|
|
|
46 |
Augmenting Treatment Effects of Voice Therapy in Parkinson Disease |
Recruiting |
NCT02265315
|
|
|
47 |
Real World Testing of a Brain-Computer Interface to Operate a Commercial Augmentative and Alternative Communication System |
Recruiting |
NCT04026581
|
|
|
48 |
Efficacy of an Intervention for the Children With Severe Speech Sounds Disorders |
Recruiting |
NCT03700151
|
|
|
49 |
Perioperative Optic Nerve Sheath Diameter As A Predictor Of Early Tacrolimus Neurotoxicity In Living Donor Liver Transplantation |
Recruiting |
NCT03799770
|
|
|
50 |
Babble Boot Camp: Preventing Speech and Language Disorders in Children With Classic Galactosemia |
Recruiting |
NCT03838016
|
|
|
Cochrane evidence based reviews: speech disorders
|